"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of PDAC in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
Study Details
Study Description
Brief Summary
To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.
Purpose: To improve the rates of early detection of pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Incidence of PDAC at 3 years [3yrs]
Secondary Outcome Measures
- • Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years [baseline and 3yrs]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age > 50 years
-
Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
-
Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not > 125 mg/dl
-
END-PDAC score > 2
Exclusion Criteria:
-
Known or newly detected chronic pancreatitis
-
Past history of pancreatic cancer
-
History of steroid use
-
Contraindications for EUS
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Asian Institute of Gastroenterology, India
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PDAC-NOD-001